Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Abstract Background Due to the increasing number of trials with immune checkpoint inhibitors (ICIs) in the first‐line therapy of non‐small cell lung cancer (NSCLC) patients, we performed a systematic review and meta‐analyses to investigate the difference between anti PD‐1 and PD‐L1 antibodies, used...

Full description

Bibliographic Details
Main Authors: Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
anti‐PD1
anti‐PD‐L1
immunotherapy
meta‐analysis
NSCLC
Online Access:https://doi.org/10.1111/1759-7714.13867

Internet

https://doi.org/10.1111/1759-7714.13867

Similar Items